Hepatic hypertrophic osteoarthropathy and liver transplantation

Hepatic hypertrophic osteoarthropathy (HOA) is a rare and disabling condition. It tends to respond poorly to conservative management such as analgesia or intra-articular injection of steroids. A recent article highlighted the benefits of successful liver transplantation in producing remission of this painful arthritus. We report a case of HOA which developed nine years after orthotopic liver transplantation (OLT).

A 44 year old man presented in February 1993 with three week history of pain and swelling of his wrists, knees and ankles. He had no previous arthritic symptoms. In 1979, he had developed primary sclerosing cholangitis and had undergone liver transplantation in 1985. A Roux-en-Y procedure was performed in 1991 for biliary stasis. Contrast cholangiography later that year demonstrated good biliary drainage. No strictures were present, but abnormal tapering of the distal biliary tree was noted. Because of continuing cholestasis, a liver biopsy was performed in September 1992. This showed chronic active hepatitis but no evidence of rejection. There was no recurrence of his original disease.

Examination revealed toe but no finger clubbing and he was markedly icteric. There was synovitis affecting the wrists, knees, and ankles, with tenderness proximal to the joints. Synovial fluid was non-inflammatory.

Radiographs of the relevant joints showed a marked periosteal reaction consistent with HOA (figure). Chest radiograph was normal. The knee effusions responded to intra-articular steroid injection and the arthritis symptoms have resolved. However, his liver tests have continued to deteriorate slowly and repeat transplantation is being considered.

The pathogenesis of HOA is unknown. Hormonal, circulatory, and neurogenic factors have been implicated. It is thought that a growth factor mediated effect is probably involved leading to elevation of the periosteum, new bone deposition and oedema of the surrounding tissues. This factor may accumulate as a result of impaired hepatic clearance or may be produced in excess by the liver as part of its response to disease. Hepatic HOA is rare. It is usually associated with cholestasis and is most commonly seen with primary biliary cirrhosis, chronic active hepatitis, and post-hepatic cirrhosis.

Liver transplantation, besides resulting in improved hepatic function, has also been shown to cause resolution of the joint symptoms of hepatic HOA. This may be because the stimulus for HOA, presumably resulting from the abnormal liver, has been removed. The syndrome can, however, occur novo after liver transplantation, in those with chronic rejection, or with recurrence of the underlying disease.

This patient has had two separate liver diseases. It is interesting that HOA did not occur in association with sclerosing cholangitis, but developed later with active inflammation in the grafted liver. While a minority of patients respond poorly to conservative management, this man’s symptoms resolved with intra-articular steroid administration and NSAIDs. If he undergoes repeat liver transplantation, it is possible that complete resolution of his HOA will be obtained.

Cytokine therapy in rheumatoid arthritis

The leader by Giles Campion has given a sure foundation on which to base our thoughts about cytokines, but is sparse on practical proposals.

For example, a recent Lancet article from Birmingham emphasised the early onset of osteoporosis in patients with rheumatoid arthritis (RA). We know that interleukins (IL) 1 and 6 and tumour necrosis factor alpha (TNFalpha) all playa part in causing osteoporosis, and the indications are that IL-1 receptor antagonist production is relatively poor in RA.

Hence one application that will require trial in several different or combined centres will be the administration of IL-1 receptor antagonist, to see if osteoporosis is ameliorated.

GAYE CUNNANE
ANN-MARIE O’BRYNE
JOHN Hegarty
OLIVER FITZGERALD
Department of Rheumatology
University College Dublin
St Vincent’s Hospital
Eml Park, Dublin 4
Ireland

Correspondence to: Dr Gaye Cunnane, Education and Research Centre, St Vincent’s Hospital, Dublin 4, Ireland

Antibodies to nuclear antigens in three patients with scleroderma and asthma

We read with interest the report of Martin et al regarding autoantibodies to centromere and histone in patients with scleroderma and severe pulmonary and vascular disease. During the past two years we have been following up female patients with scleroderma (two with localised scleroderma and one with diffuse scleroderma) and asthma, aged 40, 48, and 77, respectively; the onset of scleroderma had been preceded by asthma in each of them. The first two patients were atopic. Accompanying diseases were acne rosacea (first patient), thyroid adenoma (second), and diabetes mellitus type II (third patient). The diabetes in the last patient had begun 30 years ago after menopause.

We should like to report that all the patients had a history of atopic diseases and previous evidence of pulmonary embolism were found in all patients; none had symptoms suggestive of Sjögren’s syndrome. The serum IgE values were increased in the first two patients. All patients had positive antinuclear antibodies (ANA) with a pattern of nuclear autoantibodies (NANA) on indirect immunofluorescence on HEp-2 cells in titre 1:80 with a speckled pattern of immunofluorescence. The second patient had positive DNA antibodies (enzyme linked immunosorbent assay (ELISA)), and the second and third patients positive antibodies to histone 2A (ELISA). None of the three had Ro(SS-A) or La(SS-B) antibodies. The two patients also had asthma. These cases could be included in the group of any overlap syndromes. The question is whether asthma is a manifestation of fibrosis, or the two diseases are independent entities. The scleroderma involves only the skin in two of the patients. Spirometry showed an obstructive defect of ventilation in all three patients. The increase in IG E in the sera of two patients suggests involvement of reaginic type reactions. The ANA positivity suggests type II and III immune reactions.

We found no published reports of a combination of scleroderma, asthma, and positive ANA. The presence of two diseases—scleroderma and asthma—raises the following issues:

(1) The role of scleroderma as a cause for the development of asthma in these patients. The pulmonary involvement in scleroderma is very common. It is of a restrictive type, while in asthma, obstruction of the airways is a characteristic feature. Our data support the notion of an independent development of asthma.

(2) The role of the endothelial system in the development of scleroderma. It is well known that rheumatic diseases are more frequent in females. Asthma also suffer from rosacea more often and the appearance of the disease may be linked to the climacteric. It is notable that two of our patients had accompanying endocrine diseases, thyroid adenoma and diabetes. The combination of asthma with scleroderma and endocrine disorders in our three patients warrants further investigation of this association.

Nikolov

Department of Dermatology, Sofia, Bulgaria

M BALEVA
T VULCHEVA
Centre of Allergology

Ehlers Danlos syndrome and osteoporosis

Ehlers Danlos syndrome (EDS) is a group of inherited connective tissue disorders with extreme genetic and clinical variability. The clinical manifestations of EDS are a result of abnormalities in collagen types 1 and 3, the main proteins of skin, ligament, tendons, blood vessels, and internal viscera. Type 1 collagen is also the main protein constituent of the bone matrix and its abnormalities form the molecular basis of osteogenesis imperfecta (OI). EDS is therefore quite closely linked to OI and the two conditions are known to coexist. In spite of this there are no detailed studies available on bone mineral content and bone distribution in EDS patients.

In the past three years we have seen seven patients with EDS and assessed bone densities in the lumbar spine and hip using dual energy x-ray absorptiometry. A 65 year old lady referred from the orthopaedic department for investigations of a wedge fracture of the L2 vertebra. She did not have any obvious precipitating causes for osteoporosis in her past medical, menstrual,
Author's reply

Giles V Campion

do: 10.1136/ard.53.12.840-c

Updated information and services can be found at:
http://ard.bmj.com/content/53/12/840.3.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/